IP Library Granted Patent US 9,000,029
Granted Patent B2
US 9,000,029 · App. 14/530,532 · Granted Apr 7, 2015

Proline sulfonamide derivatives as orexin receptor antagonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,000,029
App. No.
14/530,532
Granted
Apr 7, 2015
Kind
B2
Abstract

The present invention relates to (S)-proline sulfonamide compounds of formula (I) wherein R 1 and R 2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.

Claims (13)

1. A method for antagonizing an orexin receptor in a subject having an anxiety disorder, comprising administering to said subject a pharmaceutical composition comprising the compound (S)-1-(4-Methoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (3,5-dimethyl-phenyl)-amide.

2. A method according to claim 1 , wherein said anxiety disorder is selected from a phobic anxiety or a post-traumatic stress disorder.

3. A method according to claim 1 , wherein said pharmaceutical composition comprises a pharmaceutically acceptable carrier.

4. A method according to claim 2 , wherein said pharmaceutical composition comprises a pharmaceutically acceptable carrier.

5. A method according to claim 3 , wherein said compound is (S)-1-(4-Methoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (3,5-dimethyl-phenyl)-amide in free form.

6. A method according to claim 4 , wherein said compound is (S)-1-(4-Methoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (3,5-dimethyl-phenyl)-amide in free form.

7. A method according to claim 2 , wherein said anxiety disorder is a phobic anxiety.

8. A method according to claim 2 , wherein said anxiety disorder is a post-traumatic stress disorder.

9. A method according to claim 4 , wherein said anxiety disorder a phobic anxiety.

10. A method according to claim 4 , wherein said anxiety disorder is a post-traumatic stress disorder.

11. A method according to claim 6 , wherein said anxiety disorder is a phobic anxiety.

12. A method according to claim 6 , wherein said anxiety disorder is a post-traumatic stress disorder.

13. A method according to claim 1 , wherein said anxiety disorder is a circumscribed threat induced anxiety disorder.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042464 FRAME: 0407. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 28, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 043017/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 042464/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2014
From: BOSS, CHRISTOPH; BROTSCHI, CHRISTINE; GATFIELD, JOHN; GUDE, MARKUS; HEIDMANN, BIBIA; SIFFERLEN, THIERRY; WILLIAMS, JODI T.
To: ACTELION PHARMACEUTICALS LTD.
Reel/Frame 034557/0309 →